1. Neurodegenerative biomarkers and inflammation in patients with propionic and methylmalonic acidemias: effect of L-carnitine treatment.
- Author
-
Dos Reis BG, Becker GS, Marchetti DP, de Moura Coelho D, Sitta A, Wajner M, and Vargas CR
- Subjects
- Humans, Male, Female, Inflammation metabolism, Inflammation drug therapy, Propionic Acidemia drug therapy, Cytokines blood, Child, Child, Preschool, Adolescent, Adult, Neurodegenerative Diseases drug therapy, Neurodegenerative Diseases blood, Oxidative Stress drug effects, C-Reactive Protein analysis, C-Reactive Protein metabolism, Carnitine therapeutic use, Biomarkers blood, Amino Acid Metabolism, Inborn Errors blood, Amino Acid Metabolism, Inborn Errors drug therapy
- Abstract
Propionic and methylmalonic acidemias (PAcidemia and MMAcidemia, respectively) are genetic disorders characterized by acute metabolic decompensation and neurological complications. L-carnitine (LC) is effective in reducing toxic metabolites that are related to the pathophysiology of these diseases. Therefore we investigated biomarkers of inflammation (cytokines and C-reactive protein (CRP)), neurodegeneration (BDNF, NCAM-1 and cathepsin-D) and biomolecules oxidation (sulfhydryl content and thiobarbituric acid-reactive species (TBARS)), as well as carnitine concentrations in untreated patients with PAcidemia and MMAcidemia, in patients under treatment with LC and a protein-restricted diet for until 2 years and in patients under the same treatment for more than 2 years. It was verified an increase of CRP, IL-6, IL-8, TNF-α, IL-10, NCAM-1 and cathepsin-D in untreated patients compared to controls. On the other hand, reduced levels of TNF-α, CRP, IL-10, NCAM-1 and cathepsin-D were found in plasma from treated patients, as well as increased concentrations of LC. Furthermore, oxidative biomarkers were increased in untreated patients and were normalized with the prolonged treatment with LC. In conclusion, this work shows, for the first time, that inflammatory and neurodegenerative peripheral biomarkers are increased in patients with PAcidemia and MMAcidemia and that treatment with LC is effective to protect against these alterations., Competing Interests: Declarations Ethics approval This study was approved by the Ethics Committee of Hospital de Clínicas de Porto Alegre, RS, Brazil, and the informed consent was obtained according to the guidelines of the committee (Project number 20230157). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Consent to participate Informed consent was obtained from all patients for being included in the study. Competing interests The authors declare no competing interests., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF